Results of a 3 month treatment with metformin in patients with type 2 diabetes mellitus associated with ischaemic heart disease

Abstract

MSEI of Ukraine «Ukrainian Medical Stomatological Academy«, Poltava the aim of the research was to investigate the effectiveness of mid-term inclusion of Metformin in the complex therapy in patients with diabetes type 2 in combination with IHD for the rational justification of timing, doses of the drug. Materials and methods. 52 man suffering from diabetes type 2 on background of ischaemic heart disease have been observed. An effect of included Metformin at mid-term rate (3 months) was estimated. The blood rates are observed (total cholesterol (TC), HDL-cholesterol, total lipids (TL), triglycerides (TG), β-lipoproteins, glycated hemoglobin, C-peptide) and anti inflammatory markers (IL-1β, IL-6, IL-8 and TNF-α). Results. In patients with diabetes type 2 on background of ischaemic heart disease during 3 months under the action of metformin significant decrease in body weight, waist circumference, BMI, concentration of total cholesterol, C-peptide and insulin resistance index and cytokines level IL-1β, IL-6 and TNF-α were observed. Conclusion. The obtained results indicate the purpose of Metformin prescription in patients with diabetes type 2 and IHD in the continuation of 3 months; it is an effective and safe method of treatment of such patients.